The role of RIM1alpha in BDNF-enhanced glutamate release.
Brain-derived neurotrophic factor (BDNF) is known to activate proline-directed Ser/Thr protein kinases and to enhance glutamatergic transmission via a Rab3a-dependent molecular pathway. The identity of molecular targets in BDNF's action on Rab3a pathway, a synaptic vesicle protein involved in vesicle trafficking and synaptic plasticity, is not fully known. Here we demonstrate that BDNF enhances depolarization-evoked efflux of [(3)H]-glutamate from nerve terminals isolated from the CA1 region of the hippocampus. BDNF also potentiated hyperosmotic shock-evoked [(3)H]-glutamate efflux, indicating an effect on the size of the readily releasable pool. This effect of BDNF was completely abolished in nerve terminals derived from Rim1alphaKO (Rab3 interacting molecule 1alpha null mutant) mice. Using in vitro phosphorylation assays we identified two novel phosphorylation sites, Ser447 and Ser745 that were substrates for ERK2, a proline-directed kinase known to be activated by BDNF. The pSer447 site was phosphorylated under resting conditions in hippocampal CA1 nerve terminals and its phosphorylation was enhanced by BDNF treatment, as indicated by the use of a pSer447-RIM1alpha antibody we have developed. Together these findings identify RIM1alpha, a component of the Rab3a molecular pathway in mediating presynaptic plasticity, as a necessary factor in BDNF's enhancement of [(3)H]-glutamate efflux from hippocampal CA1 nerve terminals and indicate a possible role for RIM1alpha phosphorylation in BDNF-dependent presynaptic plasticity.
Simsek-Duran
Fatma
F
Department of Pathology and Anatomy, Eastern Virginia Medical School, 700 W. Olney Road Norfolk, VA 23507, USA.
Lonart
György
G
D000704:Analysis of Variance; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000172:deficiency / Q000502:physiology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000235:genetics; D018698:Glutamic Acid / Q000378:metabolism*; D006624:Hippocampus / Q000648:ultrastructure; D066298:In Vitro Techniques; D048730:MAP Kinase Kinase Kinase 2 / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010766:Phosphorylation / Q000187:drug effects; D012694:Serine / Q000378:metabolism; D013395:Sucrose / Q000494:pharmacology; D013549:Sweetening Agents / Q000494:pharmacology; D013574:Synaptosomes / Q000187:drug effects* / Q000378:metabolism*; D013997:Time Factors; D014316:Tritium / Q000378:metabolism
D019208:Brain-Derived Neurotrophic Factor; C491490:Rims1 protein, mouse; D013549:Sweetening Agents; D014316:Tritium; D018698:Glutamic Acid; D012694:Serine; D013395:Sucrose; D048730:MAP Kinase Kinase Kinase 2; D019204:GTP-Binding Proteins